PHAXIAM THERAPEUTICS S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.875 EUR | +0.17% |
|
+19.79% | -37.50% |
| 06-12 | Phaxiam: capital increase of ten million euros | CF |
| 04-15 | Phaxiam initiates trial in infective endocarditis | CF |
| Sales 2024 * | 1.05M 1.13M 1.54M | Sales 2025 * | 1.6M 1.71M 2.35M | Capitalization | 12.15M 13.02M 17.85M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 0 | Net income 2025 * | 1M 1.07M 1.47M | EV / Sales 2024 * | 12 x |
| Net Debt 2024 * | 450K 482K 661K | Net Debt 2025 * | 10.55M 11.3M 15.5M | EV / Sales 2025 * | 14.2 x |
| P/E ratio 2024 * |
-1.49
x | P/E ratio 2025 * |
-2.25
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 day | +0.17% | ||
| 1 week | +19.79% | ||
| Current month | -4.01% | ||
| 1 month | -5.89% | ||
| 3 months | -2.21% | ||
| 6 months | -36.67% | ||
| Current year | -37.50% |
1 week
2.00
3.00
1 month
2.003.08
Current year
2.004.70
1 year
2.008.78
3 years
2.0075.80
5 years
2.00114.60
10 years
2.00402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-19 | 2 | -4.53% | 28,957 |
| 24-06-18 | 2.095 | +1.21% | 11,860 |
| 24-06-17 | 2.07 | -1.43% | 12,034 |
| 24-06-14 | 2.1 | -12.86% | 23,080 |
| 24-06-13 | 2.41 | +0.42% | 29,580 |
End-of-day quote Euronext Paris, June 10, 2024
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-06-28
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2
EUR
Average target price
6.819
EUR
Spread / Average Target
+240.95%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.50% | 13.05M | |
| +14.84% | 121B | |
| +18.31% | 112B | |
| +4.40% | 22.57B | |
| -18.26% | 20.82B | |
| -16.66% | 16.19B | |
| -42.36% | 16.17B | |
| -14.23% | 16.3B | |
| -0.68% | 13.17B | |
| +21.87% | 11.11B |
- Stock Market
- Equities
- PHXM Stock
